טוען...
PAN-CANCER EFFICACY OF VEMURAFENIB IN BRAF(V600)-MUTANT NON-MELANOMA CANCERS
BRAF V600 mutations occur in a wide range of tumor types and RAF inhibition has become standard in several of these cancers. Despite this progress, BRAF V600 mutations have historically been considered a clear demonstration of tumor lineage context-dependent oncogene addiction, based predominantly o...
שמור ב:
| הוצא לאור ב: | Cancer Discov |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7196502/ https://ncbi.nlm.nih.gov/pubmed/32029534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-1265 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|